Cargando…
Epigenetic drugs induce the potency of classic chemotherapy, suppress post-treatment re-growth of breast cancer, but preserve the wound healing ability of stem cells
Epigenetic therapy augments neoadjuvant chemotherapy (NACT) in breast cancer and may aid post-surgical wound healing affected by NACT. Our study investigates: (1) The cytotoxicity of classic paclitaxel chemotherapy on triple negative breast cancer (TNBC) independently and in combination with epigene...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993057/ https://www.ncbi.nlm.nih.gov/pubmed/35389825 http://dx.doi.org/10.1080/15384047.2022.2052540 |
_version_ | 1784683834796670976 |
---|---|
author | Zheng, Andrew Bilbao, Michelle Sookram, Janhvi Linden, Kimberly M. Morgan, Andrew B. Ostrovsky, Olga |
author_facet | Zheng, Andrew Bilbao, Michelle Sookram, Janhvi Linden, Kimberly M. Morgan, Andrew B. Ostrovsky, Olga |
author_sort | Zheng, Andrew |
collection | PubMed |
description | Epigenetic therapy augments neoadjuvant chemotherapy (NACT) in breast cancer and may aid post-surgical wound healing affected by NACT. Our study investigates: (1) The cytotoxicity of classic paclitaxel chemotherapy on triple negative breast cancer (TNBC) independently and in combination with epigenetic drugs. (2) The sustainable inhibition of breast cancer regrowth following paclitaxel and epigenetic therapies. (3) The effects of paclitaxel with and without epigenetic therapy on the post-treatment viability and wound healing potential of adipose stem cells (ASCs). Cytotoxicity assays were performed on TNBC and ASCs. Cells were treated and recovered in drug-free medium. Cell viability was measured via cell counts and MTT assays. W -ound healing was tested with scratch assays. The combination of epigenetic drugs shows increased toxicity against TNBC cells compared to standard chemotherapy alone. Moreover, the combination of paclitaxel with epigenetic treatments causes cancer toxicity that is sustainable to TNBC cells after the drugs’ removal with minimal effect on ASCs wound healing ability. The use of epigenetic drugs in addition to standard chemotherapy is cytotoxic to TNBC cells and prevents post-treatment recovery of TNBC while maintaining ASC wound healing ability. This strategy may be useful in maximizing post-surgical wound healing following NACT in TNBC. |
format | Online Article Text |
id | pubmed-8993057 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-89930572022-04-09 Epigenetic drugs induce the potency of classic chemotherapy, suppress post-treatment re-growth of breast cancer, but preserve the wound healing ability of stem cells Zheng, Andrew Bilbao, Michelle Sookram, Janhvi Linden, Kimberly M. Morgan, Andrew B. Ostrovsky, Olga Cancer Biol Ther Research Paper Epigenetic therapy augments neoadjuvant chemotherapy (NACT) in breast cancer and may aid post-surgical wound healing affected by NACT. Our study investigates: (1) The cytotoxicity of classic paclitaxel chemotherapy on triple negative breast cancer (TNBC) independently and in combination with epigenetic drugs. (2) The sustainable inhibition of breast cancer regrowth following paclitaxel and epigenetic therapies. (3) The effects of paclitaxel with and without epigenetic therapy on the post-treatment viability and wound healing potential of adipose stem cells (ASCs). Cytotoxicity assays were performed on TNBC and ASCs. Cells were treated and recovered in drug-free medium. Cell viability was measured via cell counts and MTT assays. W -ound healing was tested with scratch assays. The combination of epigenetic drugs shows increased toxicity against TNBC cells compared to standard chemotherapy alone. Moreover, the combination of paclitaxel with epigenetic treatments causes cancer toxicity that is sustainable to TNBC cells after the drugs’ removal with minimal effect on ASCs wound healing ability. The use of epigenetic drugs in addition to standard chemotherapy is cytotoxic to TNBC cells and prevents post-treatment recovery of TNBC while maintaining ASC wound healing ability. This strategy may be useful in maximizing post-surgical wound healing following NACT in TNBC. Taylor & Francis 2022-04-07 /pmc/articles/PMC8993057/ /pubmed/35389825 http://dx.doi.org/10.1080/15384047.2022.2052540 Text en This work was authored as part of the Contributor’s official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 U.S.C. 105, no copyright protection is available for such works under U.S. Law. https://creativecommons.org/publicdomain/mark/1.0/This is an Open Access article that has been identified as being free of known restrictions under copyright law, including all related and neighbouring rights (https://creativecommons.org/publicdomain/mark/1.0/). You can copy, modify, distribute and perform the work, even for commercial purposes, all without asking permission. |
spellingShingle | Research Paper Zheng, Andrew Bilbao, Michelle Sookram, Janhvi Linden, Kimberly M. Morgan, Andrew B. Ostrovsky, Olga Epigenetic drugs induce the potency of classic chemotherapy, suppress post-treatment re-growth of breast cancer, but preserve the wound healing ability of stem cells |
title | Epigenetic drugs induce the potency of classic chemotherapy, suppress post-treatment re-growth of breast cancer, but preserve the wound healing ability of stem cells |
title_full | Epigenetic drugs induce the potency of classic chemotherapy, suppress post-treatment re-growth of breast cancer, but preserve the wound healing ability of stem cells |
title_fullStr | Epigenetic drugs induce the potency of classic chemotherapy, suppress post-treatment re-growth of breast cancer, but preserve the wound healing ability of stem cells |
title_full_unstemmed | Epigenetic drugs induce the potency of classic chemotherapy, suppress post-treatment re-growth of breast cancer, but preserve the wound healing ability of stem cells |
title_short | Epigenetic drugs induce the potency of classic chemotherapy, suppress post-treatment re-growth of breast cancer, but preserve the wound healing ability of stem cells |
title_sort | epigenetic drugs induce the potency of classic chemotherapy, suppress post-treatment re-growth of breast cancer, but preserve the wound healing ability of stem cells |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993057/ https://www.ncbi.nlm.nih.gov/pubmed/35389825 http://dx.doi.org/10.1080/15384047.2022.2052540 |
work_keys_str_mv | AT zhengandrew epigeneticdrugsinducethepotencyofclassicchemotherapysuppressposttreatmentregrowthofbreastcancerbutpreservethewoundhealingabilityofstemcells AT bilbaomichelle epigeneticdrugsinducethepotencyofclassicchemotherapysuppressposttreatmentregrowthofbreastcancerbutpreservethewoundhealingabilityofstemcells AT sookramjanhvi epigeneticdrugsinducethepotencyofclassicchemotherapysuppressposttreatmentregrowthofbreastcancerbutpreservethewoundhealingabilityofstemcells AT lindenkimberlym epigeneticdrugsinducethepotencyofclassicchemotherapysuppressposttreatmentregrowthofbreastcancerbutpreservethewoundhealingabilityofstemcells AT morganandrewb epigeneticdrugsinducethepotencyofclassicchemotherapysuppressposttreatmentregrowthofbreastcancerbutpreservethewoundhealingabilityofstemcells AT ostrovskyolga epigeneticdrugsinducethepotencyofclassicchemotherapysuppressposttreatmentregrowthofbreastcancerbutpreservethewoundhealingabilityofstemcells |